Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 8/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.70 |
| ▸ | DRD4 | P21917 | 3/20 | 0.70 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.70 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | HTR1B | P28222 | 1/20 | 0.70 |
| ▸ | HTR7 | P34969 | 1/20 | 0.70 |
| ▸ | HTR2B | P41595 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | BLM | P54132 | 1/20 | 0.64 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7474354 | 1.00 | HTR1A (1.00) | HTR1AMEN1KMT2AADRA1ADRD4 | |
| SCHEMBL8010247 | 1.00 | HTR1A (1.00) | HTR1AMEN1KMT2AADRA1ADRD4 | |
| SCHEMBL27351354 | 0.84 | HTR1A (0.73) | HTR1AMEN1KMT2AADRA1ADRD4 | |
| SCHEMBL27347000 | 0.84 | HTR1A (0.73) | HTR1AMEN1KMT2AADRA1ADRD4 | |
| SCHEMBL14275261 | 0.84 | HTR1A (0.83) | HTR1AMEN1KMT2AADRA1ADRD4 | |
| Way-100,635 SCHEMBL13398069 | 0.82 | HTR1A (1.00) | HTR1AMEN1KMT2AADRA1ADRD4 | |
| Way-100,635 SCHEMBL84178 | 0.82 | HTR1A (1.00) | HTR1AMEN1KMT2AADRA1ADRD4 | |
| Way-100,635 SCHEMBL29451114 | 0.82 | HTR1A (1.00) | HTR1AMEN1KMT2AADRA1ADRD4 | |
| Way-100,635 SCHEMBL30720034 | 0.82 | HTR1A (1.00) | HTR1AMEN1KMT2AADRA1ADRD4 | |
| SCHEMBL8136258 | 0.82 | HTR1A (0.70) | HTR1AMEN1KMT2AADRA1ADRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0512755-B1 | Piperazine derivatives | WYETH JOHN & BROTHER LTD (GB) | 1994-12-14 | — | — | EP | claimed |
| US-7731940-B2 | N-(2-[4-(2-methoxyphenyl)piperazinyl]ethyl)-N-(2-pyridyl)-N-(4-18F-fluoro-methylcyclohexane)carboxamide, used for treating panic, bipolar or seizure disorders, and as a quantitative tool for measuring serotonin concentration in the brain | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-06-08 | — | — | US | disclosed |
| US-20070196271-A1 | COMPOSITIONS AND METHODS RELATED TO SEROTONIN 5-HT1A RECEPTORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-08-23 | — | — | US | disclosed |
| EP-0763024-B1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF PIPERAZINE DERIVATIVES | WYETH JOHN & BROTHER LTD (GB) | 2002-08-14 | — | — | EP | disclosed |
| US-6395902-B1 | NOVEL INTERMEDIATES IN THE PREPARATION OF PHARMACEUTICALLY USEFUL PYRIDINE DERIVATIVES AS END COMPOUNDS | JOHN WYETH & BROTHER LIMITED (GB) | 2002-05-28 | — | — | US | disclosed |
| US-6175012-B1 | REACTING 4-METHYL-3-(2-PYRIDYL)-(1,2,3,)OXATHIAZOLIDINE-2,2-DIOXIDE, FOR EXAMPLE WITH A 1-(ARYL OR HETEROARYL)PIPERAZINE TO FORM A 1-(HETERO)ARYL-4-(HETEROARYLAMINOALKYL)PIPERAZINE; INTERMEDIATE TO 5-HT1A ANTAGONIST DRUGS | JOHN WYETH & BROTHER LTD. (GB) | 2001-01-16 | — | — | US | disclosed |
| US-6133449-A | Processes and intermediates for the preparation of piperazine derivatives | JOHN WYETH & BROTHER LTD. (GB) | 2000-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070196271-A1 | COMPOSITIONS AND METHODS RELATED TO SEROTONIN 5-HT1A RECEPTORS | HTR5A, HTR1A, HTR7 | HTR1A 2/4885MEN1 953/4885KMT2A 4007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.